|
1
|
Kulkarni HR, Singh A and Baum RP: Advances
in the diagnosis of neuroendocrine neoplasms. Semin Nucl Med.
46:395–404. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rindi G, Mete O, Uccella S, Basturk O, La
Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M
and Asa SL: Overview of the 2022 WHO classification of
neuroendocrine neoplasms. Endocr Pathol. 33:115–154.
2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shah MH, Goldner WS, Benson AB, Bergsland
E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, et
al: Neuroendocrine and adrenal tumors, version 2.2021, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
19:839–868. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rizen EN and Phan AT: Neuroendocrine
tumors: A relevant clinical update. Curr Oncol Rep. 24:703–714.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mastracci L, Rindi G, Grillo F, Solcia E,
Campora M, Fassan M, Parente P, Vanoli A and La*Rosa S:
Neuroendocrine neoplasms of the esophagus and stomach. Pathologica.
113:5–11. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cives M and Strosberg JR:
Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin.
68:471–487. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Abdel-Rahman O and Fouad M:
Everolimus-based combination for the treatment of advanced
gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs):
Biological rationale and critical review of published data. Tumour
Biol. 36:467–478. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ye BX, Heng D, Jiang LQ, Wang Y, Zhang HJ
and Lin L: Application of AJCC/UICC and WHO-2010 classifications
for GEP-NEN in Chinese patients. J Dig Dis. 16:264–271.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chi Y, Du F, Zhao H, Wang JW and Cai JQ:
Characteristics and long-term prognosis of patients with rectal
neuroendocrine tumors. World J Gastroenterol. 20:16252–16257.
2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Division of Digestive Diseases, Chinese
Society of Pathology; 2020 Chinese Consensus on the Pathological
Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine
Neoplasms Experts Group. Chinese consensus on the pathological
diagnosis of gastrointestinal and pancreatic neuroendocrine
neoplasms(2020). Zhonghua Bing Li Xue Za Zhi. 50:14–20.
2021.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
11
|
Clark OH, Benson AB III, Berlin JD, Choti
MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A,
Kulke MH, et al: NCCN clinical practice guidelines in oncology:
Neuroendocrine tumors. J Natl Compr Canc Netw. 7:712–747.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vinik AI, Woltering EA, Warner RR, Caplin
M, O'Dorisio TM, Wiseman GA, Coppola D and Go VL: North American
Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines
for the diagnosis of neuroendocrine tumor. Pancreas. 39:713–734.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ambrosini V, Kunikowska J, Baudin E, Bodei
L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C,
Falconi M, et al: Consensus on molecular imaging and theranostics
in neuroendocrine neoplasms. Eur J Cancer. 146:56–73.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen X, He S, Yan Q, Pan H, Lu X, Zhang J,
Zhou J, Chen L, Zhang X and Shi M: Diagnosis value of
neuroendocrine differentiation in gastric cancer by
immunohistochemistry and electron microscope. Chin J Gastroenterol
Hepatol. 16:447–450. 2007.
|
|
15
|
Li ZS and Li Q: The latest 2010 WHO
classification of tumors of digestive system. Zhonghua Bing Li Xue
Za Zhi. 40:351–354. 2011.PubMed/NCBI(In Chinese).
|
|
16
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jacob J, Chargari C, Helissey C, Ferrand
FR, Ceccaldi B, Le Moulec S, Bauduceau O, Fayolle M and Védrine L:
Neuroendocrine carcinoma of the digestive tract: A literature
review. Rev Med Interne. 34:700–705. 2013.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
18
|
Kulke MH, Shah MH, Benson AB III,
Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF,
Fanta P, Giordano T, et al: Neuroendocrine tumors, version 1.2015.
J Natl Compr Canc Netw. 13:78–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Maggard MA, O'Connell JB and Ko CY:
Updated population-based review of carcinoid tumors. Ann Surg.
240:117–122. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li TT, Qiu F, Qian ZR, Wan J, Qi XK and Wu
BY: Classification, clinicopathologic features and treatment of
gastric neuroendocrine tumors. World J Gastroenterol. 20:118–125.
2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kunz PL, Reidy-Lagunes D, Anthony LB,
Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK,
Klimstra DS, et al: Consensus guidelines for the management and
treatment of neuroendocrine tumors. Pancreas. 42:557–577.
2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Boyce M and Thomsen L: Gastric
neuroendocrine tumors: Prevalence in Europe, USA, and Japan, and
rationale for treatment with a gastrin/CCK2 receptor antagonist.
Scand J Gastroenterol. 5:550–559. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vos B, Rozema T, Miller RC, Hendlisz A,
Van Laethem JL, Khanfir K, Weber DC, El Nakadi I and Van*Houtte P:
Small cell carcinoma of the esophagus: A multicentre rare cancer
network study. Dis Esophagus. 24:258–264. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Niederle MB and Niederle B: Gastric
neuroendocrine tumors. Endoscopic and surgical treatment. Chirurg.
82:574–582. 2011.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
25
|
Soga J: Early-stage carcinoids of the
gastrointestinal tract: An analysis of 1914 reported cases. Cancer.
103:1587–1595. 2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Scardoni M, Vittoria E, Volante M, Rusev
B, Bersani S, Mafficini A, Gottardi M, Giandomenico V, Malleo G,
Butturini G, et al: Mixed adenoneuroendocrine carcinomas of the
gastrointestinal tract: Targeted next-generation sequencing
suggests a monoclonal origin of the two components.
Neuroendocrinology. 100:310–316. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ramage JK, Ahmed A, Ardill J, Bax N, Breen
DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, et al:
Guidelines for the management of gastroenteropancreatic
neuroendocrine (including carcinoid) tumours (NETs). Gut. 61:6–32.
2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hörsch D, Schmid KW, Anlauf M, Darwiche K,
Denecke T, Baum RP, Spitzweg C, Grohé C, Presselt N, Stremmel C, et
al: Neuroendocrine tumors of the bronchopulmonary system (typical
and atypical carcinoid tumors): Current strategies in diagnosis and
treatment. Conclusions of an expert meeting February 2011 in
Weimar, Germany. Oncol Res Treat. 37:266–276. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Glinicki P and Jeske W: Chromogranin A
(CgA)-the influence of various factors in vivo and in vitro, and
existing disorders on it's concentration in blood. Endokrynol Pol.
62 (Suppl 1):S25–S28. 2011.PubMed/NCBI(In Polish).
|
|
30
|
Sciola V, Massironi S, Conte D, Caprioli
F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT and Piodi L:
Plasma chromogranin a in patients with inflammatory bowel disease.
Inflamm Bowel Dis. 15:867–871. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Pregun I, Herszényi L, Juhász M, Miheller
P, Hritz I, Patócs A, Rácz K and Tulassay Z: Effect of proton-pump
inhibitor therapy on serum chromogranin a level. Digestion.
84:22–28. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Waldum HL and Syversen U: Serum
chromogranin A in the control of patients on long-term treatment
with inhibitors of acid secretion. Eur J Clin Invest. 31:741–743.
2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Modlin IM, Kidd M, Malczewska A, Drozdov
I, Bodei L, Matar S and Chung KM: The NETest: The clinical utility
of multigene blood analysis in the diagnosis and management of
neuroendocrine tumors. Endocrinol Metab Clin North Am. 47:485–504.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Öberg K, Califano A, Strosberg JR, Ma S,
Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling
A and Paulson S: A meta-analysis of the accuracy of a
neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann
Oncol. 31:202–212. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Malczewska A, Witkowska M, Wójcik-Giertuga
M, Kuśnierz K, Bocian A, Walter A, Rydel M, Robek A, Pierzchała S,
Malczewska M, et al: Prospective evaluation of the NETest as a
liquid biopsy for gastroenteropancreatic and bronchopulmonary
neuroendocrine tumors: An ENETS center of excellence experience.
Neuroendocrinology. 111:304–319. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liu E, Paulson S, Gulati A, Freudman J,
Grosh W, Kafer S, Wickremesinghe PC, Salem RR and Bodei L:
Assessment of NETest clinical utility in a U.S. Registry-based
study. Oncologist. 24:783–790. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Famulski W, Sulkowska M, Miller-Famulska
D, Kisielewski W and Sulkowski S: Correlation between chromogranin
A, neuron-specific enolase and synaptophysin expression, and some
clinico-pathological features of colorectal cancer. Folia Histochem
Cytobiol. 39:155–156. 2001.PubMed/NCBI
|
